The Trump administration announced a recommendation to limit Tylenol use during pregnancy due to a potential link to autism, despite conflicting scientific evidence. The FDA will update Tylenol's label to reflect this, prompting criticism from the American College of Obstetricians and Gynecologists and Tylenol's manufacturer, Kenvue, who cite a lack of conclusive evidence. The administration also announced an approval process for leucovorin, a drug with limited evidence of benefit for autism symptoms, and reiterated unsubstantiated claims linking vaccines to autism.

Prepared by Olivia Bennett and reviewed by editorial team.